Itch, a skin sensation that provokes the desire to scratch, accompanies various skin diseases such as atopic dermatitis. Although H 1 histamine-receptor antagonists are the drugs of first choice for the treatment of itch, many pruritic diseases except acute urticaria do not show a good response.1) Therefore, it is important to develop new drugs that are effective against antihistamine-resistant pruritus.The fruiting body of Ganoderma lucidum (G. lucidum) KARST has been used as a crude drug in China, Japan, and Korea for the treatment of hypertension, chronic hepatitis, hyperglycemia, cancer, and chronic bronchitis.2,3) The extract of G. lucidum has been shown to have an antiallergic activity, which is mainly due to its inhibitory effect on the histamine release from mast cells. 4,5) Many antiallergic drugs generally show antipruritic activity, 6) but the antipruritic activity of G. lucidum has not yet been elucidated.Scratching, an itch-related response, can be elicited by intradermal injections of various substances, including histamine, 7) substance P, 8,9) 5-hydroxytryptamine (5-HT), 10) proteinase-activated receptor-2 (PAR 2 )-activating peptide, 11) and compound 48/80. 8,12) Scratching induced by these substances may not be mediated by the same primary afferents. 9,[13][14][15] Therefore, in the present study, we examined whether G. lucidum can ameliorate the scratching elicited by the pruritogens mentioned above in order to determine the antipruritic efficacy of G. lucidum and its possible mechanisms.
MATERIALS AND METHODS
AnimalsMale ICR mice (Japan SLC, Ltd., Shizuoka, Japan) aged 5-8 weeks and weighing 24-26 g were used. They were housed under controlled temperature (23°CϮ 1°C), humidity (60%Ϯ5%), and light (lights on from 8:00-20:00 h). Food and water were freely available. Procedures for animal experiments were approved by the Committee for Animal Experiments at the University of Toyama and were conducted in accordance with the guidelines of the Japanese Pharmacological Society.Agents 5-HT, a-methyl-5-HT, and compound 48/80were purchased from Sigma (St. Louis, MO, U.S.A.). Substance P and histamine were purchased from Peptide Institute, Inc. (Osaka, Japan) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan), respectively. Ser-Leu-Ile-Gly-Arg-Leu-NH 2 (SLIGRL-NH 2 ) was synthesized and identified by JBL with a peptide synthesizer PSSM-8 (Shimadzu Co., Kyoto, Japan) and a matrix assisted laser desorption/ionization timeof-flight (MALDI TOF)-MS Autoflex T1 (Bruker Daltonics, Billerica, MA, U.S.A.), respectively. These agents were dissolved in physiological saline and injected intradermally in a volume of 50 ml into the rostral skin of mice, the hair of which was clipped a day before the experiment was conducted.
Preparation of the Methanol Extract of G. lucidum (MEGL)The dried powder (1 kg) of G. lucidum (Koshiro Co., Ltd., Kyoto, Japan) was extracted three times with methanol for 3 h and the methanol extract was then dried; the yield of MEGL was 17.8%. MEGL was suspended in 5% gum arabic before use a...